Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Innovation is the core development strategy. we have focused our R&D efforts in antineoplastic drugs, surgery medications, and medicines that treat autoimmune diseases, metabolic diseases and cardiovascular diseases. Hengrui Pharma has been on the Pharma Exec’s annual listing of the top 50 global pharmaceutical companies for the fifth consecutive year. Hengrui Pharma ranked 24th among the top 1,000 global pharma companies announced by the Torreya in 2021. Hengrui Pharma ranked 13th in the "Top 25 global pharma companies by pipeline size " selected by Informa Pharma Intelligence in 2023.

Innovation is the core of Hengrui’s development strategy. Hengrui spent more than 850 million USD (6.35 billion RMB) in R&D in 2022, which is 29.83% of the 2022 revenue. We have built a large-scale, professional, and comprehensive innovative drug research staff of more than 5,000 people. Fourteen R&D centers were built around the world and several subsidiaries were established in the US, EU, Australia, and Japan. Hengrui Pharma has 13 in-house developed innovative products and 2 in-licensed innovative products marketed in China , more than 80 innovative candidates in the R&D stage and nearly 20 innovative products under clinical development around the world. As of June 2023, 2208 patent applications have been submitted, with 572 patents granted in China and 656 patents granted worldwide, such as the US, EU, and Japan.

Internationalization is also an important development strategy of Hengrui. By the end of 2022, Hengrui’s products have entered more than 40 countries, and will continue to accelerate global market development, focusing on emerging markets. Hengrui has established manufacturing facilities all over the country . All of its exported products meet or exceed the standards specified in the European Union and US Pharmacopoeia. We have exported injections on a large scale to the US, EU, and Japan markets. Through our international partners, Hengrui has obtained more than 20 registration approvals including injections, oral preparations and inhalation anesthetics in the EU, US and Japan to benefit more patients around the world.

Hengrui will continue its engagement in the innovation and development of treatments for various diseases spanning oncology, metabolic diseases, autoimmune diseases, cardiovascular diseases, and other therapeutic areas to benefit patients globally.